Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 236

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 236
---
 foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this guidance will have on our financial statements and disclosures. Note 3 - License, Clinical Trial and Sponsored Research Agreements Research and Development Expenses – All Licenses For the years ended December 31, 2023 and 2022, the Company recorded the following expense in research and development for licenses acquired:

| ​                                    
 ​                                    
 ($ in thousands)                     | ​ 
 ​ | ​                               
 For the year ended December 31, 
 2023                            |   ​ | ​ | ​    
 2022 |     ​ |
|:-------------------------------------|:--|:--------------------------------|----:|:--|:-----|------:|
| City of Hope National Medical Center | ​ | ​                               |   ​ | ​ | ​    |     ​ |
| IV/ICV                               | ​ | ​                               |   — | ​ | ​    |   125 |
| HER2                                 | ​ | ​                               |   — | ​ | ​    |   200 |
| CSL Behring (Calimmune)              | ​ | ​                               |  50 | ​ | ​    |    40 |
| Fortress Annual Stock Dividend       | ​ | ​                               | 477 | ​ | ​    | 1,109 |
| Total                                | ​ | $                               | 527 | ​ | $    | 1,474 |

License Agreements City of Hope IV/ICV In February 2017, the Company entered into an exclusive license agreement (the “IV/ICV License”) with COH to acquire intellectual property rights in patent applications related to the intraventricular (“IV”) and intracerebroventricular (“ICV”) methods of delivering T cells that express CARs. Pursuant to the IV/ICV License, in March 2017, the Company paid COH an upfront fee of $0.1 million. COH is eligible to receive a milestone payment totaling approximately $0.1 million, upon and subject to the achievement of a milestone, and an annual maintenance fee of $25,000. Royalty payments in the low single digits are due on net sales of licensed products. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-thirties, but no such payments are due in connection with sublicenses that are granted in conjunction with the sublicense of other